Skip to main content
UCB logo

UCB — Investor Relations & Filings

Ticker · UCB ISIN · BE0003739530 LEI · 2138008J191VLSGY5A09 BR Manufacturing
Open in API
Filings indexed 2,023 across all filing types
Latest filing 2021-03-26 Proxy Solicitation & In…
Country BE Belgium
Listing BR UCB

About UCB

https://www.ucb.com/

UCB is a global biopharmaceutical company that focuses on creating solutions for people living with severe diseases, primarily in the fields of neurology and immunology. The company's core activities include the research, development, and commercialization of pharmaceutical and biotechnology products. Guided by a patient-centric and science-driven approach, UCB is committed to innovation and sustainability. Through its UCB Ventures arm, it invests in pioneering technologies and companies with the potential to transform patient care. The company also offers personalized support services to patients and healthcare professionals during their treatment journey with a UCB medicine.

Recent filings

Filing Released Lang Actions
Proxy General Meeting 29 April 2021 - ENG - Final.pdf
Proxy Solicitation & Information Statement Classification · 99% confidence The document is explicitly titled "PROXY FOR THE GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON 29 APRIL 2021 AT 11:00 AM CEST". It contains instructions for shareholders on how to appoint a proxy holder and vote on various resolutions (approving annual accounts, remuneration reports, director appointments, etc.) scheduled for the General Meeting. This content directly relates to soliciting shareholder votes and providing necessary information for that purpose, which aligns perfectly with the definition of a Proxy Solicitation & Information Statement (PSI). It is not the AGM presentation itself (AGM-R), nor is it the full Annual Report (10-K) or a simple announcement of a report (RPA).
2021-03-26 English
Remuneration Policy 2021 Final post GNCC_TO BE PUBLISHED_FR.pdf
Remuneration Information Classification · 98% confidence The document is titled "Politique de rémunération d'UCB en 2021" (UCB Remuneration Policy for 2021) and extensively details the philosophy, principles, and proposed changes regarding compensation for the Executive Committee and the Board of Directors, referencing Belgian corporate law (CBSA) and governance codes. It explicitly mentions that this policy is to be submitted for approval at the General Shareholders' Meeting on April 29, 2021. Documents detailing executive and director compensation, especially those requiring shareholder approval, align directly with the definition of Remuneration Information (DEF 14A in the US context, which covers proxy statements detailing compensation). Although it is a policy document, its core subject matter is remuneration disclosure, making DEF 14A the most appropriate classification among the provided options, as opposed to a general proxy statement (PSI) or a general governance report (CGR).
2021-03-26 French
NBB_0019_31.12.2020_NL Final (ucb.com).pdf
Annual Report Classification · 100% confidence The document is a formal Belgian statutory annual financial filing ('Jaarrekening') for the company UCB SA. It includes identification data, a list of directors, and detailed balance sheet tables (Activa/Passiva) for the fiscal year 2020. As it contains comprehensive financial statements and is not merely an announcement or a summary, it is classified as an Annual Report (10-K equivalent in this context). FY 2020
2021-03-26 Dutch
1. Convening notice AGM 29 April 2021 - ENG - (final) - 23.03.2021.pdf
AGM Information Classification · 99% confidence The document is explicitly titled 'CONVENING NOTICE TO THE GENERAL MEETING OF SHAREHOLDERS' and details the agenda for a meeting scheduled for 'Thursday, 29 April 2021'. The agenda items cover the approval of annual accounts, remuneration reports, and crucially, the 'Appointments and renewal of mandates of directors'. This content is characteristic of materials distributed to shareholders in advance of an Annual General Meeting (AGM) to inform them of the resolutions to be voted upon. While it discusses remuneration (DEF 14A topics) and board changes (MANG topics), the overarching context is the formal notice and agenda for the AGM itself. Therefore, the most appropriate classification is AGM Information (AGM-R).
2021-03-26 English
1. Convening notice AGM 29 avril 2021 - FR - (finale) - 23.03.2021.pdf
AGM Information Classification · 100% confidence The document is explicitly titled 'CONVOCATION À L'ASSEMBLÉE GÉNÉRALE DES ACTIONNAIRES' (Notice of General Shareholders' Meeting). It details the date, time, and location of the meeting, the agenda items (including approval of annual accounts, remuneration reports, and appointment/renewal of directors), and the voting procedures. This content directly corresponds to the materials distributed to shareholders in preparation for an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM-R (AGM Information).
2021-03-26 French
1. Convening notice AGM 29 avril 2021 - NL - (finaal) - 23.03.2021.wbk.pdf
AGM Information Classification · 99% confidence The document is explicitly titled 'OPROEPING TOT DE ALGEMENE VERGADERING VAN AANDEELHOUDERS' (Call for the General Meeting of Shareholders). It details the agenda items for a meeting scheduled for April 29, 2021, including voting on the annual accounts, remuneration reports, and crucially, the appointment and renewal of mandates for directors (Agenda Item 9). This content is characteristic of the materials distributed to shareholders in advance of an Annual General Meeting (AGM) to inform their voting decisions. This aligns perfectly with the definition of AGM Information (AGM-R). Although it discusses remuneration (which could relate to DEF 14A), the primary context and structure are that of the AGM notice itself.
2021-03-26 Dutch

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.